Firsov Alexander A, Lubenko Irene Y, Vostrov Sergey N, Portnoy Yury A, Zinner Stephen H
Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya St., Moscow 119021, Russia.
Antimicrob Agents Chemother. 2005 Jul;49(7):2642-7. doi: 10.1128/AAC.49.7.2642-2647.2005.
Prediction of the relative efficacies of different fluoroquinolones is often based on the ratios of the clinically achievable area under the concentration-time curve (AUC) to the MIC, usually with incorporation of the MIC50 or the MIC90 and with the assumption of antibiotic-independent patterns of the AUC/MIC-response relationships. To ascertain whether this assumption is correct, the pharmacodynamics of seven pharmacokinetically different quinolones against two clinical isolates of Staphylococcus aureus were studied by using an in vitro model. Two differentially susceptible clinical isolates of S. aureus were exposed to two 12-h doses of ciprofloxacin (CIP) and one dose of gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), levofloxacin (LVX), moxifloxacin (MXF), and trovafloxacin (TVA) over similar AUC/MIC ranges from 58 to 932 h. A specific bacterial strain-independent AUC/MIC relationship with the antimicrobial effect (I(E)) was associated with each quinolone. Based on the I(E)-log AUC/MIC relationships, breakpoints (BPs) that are equivalent to a CIP AUC/MIC ratio of 125 h were predicted for GRX, MXF, and TVA (75 to 78 h), GAT and GEM (95 to 103 h) and LVX (115 h). With GRX and LVX, the predicted BPs were close to those established in clinical settings (no clinical data on other quinolones are available in the literature). To determine if the predicted AUC/MIC BPs are achievable at clinical doses, i.e., at the therapeutic AUCs (AUC(ther)s), the AUC(ther)/MIC50 ratios were studied. These ratios exceeded the BPs for GAT, GEM, GRX, MXF, TVA, and LVX (750 mg) but not for CIP and LVX (500 mg). AUC/MIC ratios above the BPs can be considered of therapeutic potential for the quinolones. The highest ratios of AUC(ther)/MIC50 to BP were achieved with TVA, MXF, and GEM (2.5 to 3.0); intermediate ratios (1.5 to 1.6) were achieved with GAT and GRX; and minimal ratios (0.3 to 1.2) were achieved with CIP and LVX.
不同氟喹诺酮类药物相对疗效的预测通常基于浓度 - 时间曲线下临床可达到的面积(AUC)与最低抑菌浓度(MIC)的比值,通常会纳入MIC50或MIC90,并假设AUC/MIC反应关系具有抗生素独立性模式。为了确定这一假设是否正确,我们使用体外模型研究了七种药代动力学不同的喹诺酮类药物对金黄色葡萄球菌的两种临床分离株的药效学。将金黄色葡萄球菌的两种药敏不同的临床分离株暴露于两种12小时剂量的环丙沙星(CIP)以及一种剂量的加替沙星(GAT)、吉米沙星(GEM)、格帕沙星(GRX)、左氧氟沙星(LVX)、莫西沙星(MXF)和曲伐沙星(TVA),其AUC/MIC范围相似,为58至932小时。每种喹诺酮类药物都与一种特定的、与细菌菌株无关的AUC/MIC与抗菌效果(I(E))的关系相关。基于I(E)-log AUC/MIC关系,预测GRX、MXF和TVA(75至78小时)、GAT和GEM(95至103小时)以及LVX(115小时)的断点(BP)相当于CIP AUC/MIC比值125小时。对于GRX和LVX,预测的BP接近临床设定值(文献中没有其他喹诺酮类药物的临床数据)。为了确定在临床剂量下,即治疗性AUC(AUC(ther))时是否能达到预测的AUC/MIC BP,我们研究了AUC(ther)/MIC50比值。这些比值超过了GAT、GEM、GRX、MXF、TVA和LVX(750毫克)的BP,但未超过CIP和LVX(500毫克)的BP。高于BP的AUC/MIC比值可被认为具有喹诺酮类药物的治疗潜力。TVA、MXF和GEM的AUC(ther)/MIC50与BP的比值最高(2.5至3.0);GAT和GRX的比值中等(1.5至1.6);CIP和LVX的比值最小(0.3至1.2)。